Dicerna Pharmaceuticals Corporate Bonds and Current Financial Leverage

DRNA -- USA Stock  

Quarterly Earning Report: November 4, 2019  

Dicerna Pharmaceuticals financial leverage is the degree to which the firm utilises its fixed-income securities. Companies with high leverage are usually considered to be at financial risk. Dicerna Pharmaceuticals financial risk is the risk to Dicerna Pharmaceuticals stockholders that is caused by an increase in debt. In other words with a high degree of financial leverage come high interest payments which usually reduces Earnings Per Share (EPS). Additionally see analysis of Dicerna Pharmaceuticals Fundamentals Over Time.

Dicerna Pharmaceuticals Financial Leverage Rating

Not Rated
Total Macroaxis Rating
Average S&P Rating

Dicerna Pharmaceuticals Debt to Cash Allocation

The company currently holds 2.68 M in liabilities with Debt to Equity (D/E) ratio of 1.6 which is about average as compared to similar companies. Dicerna Pharmaceuticals has Current Ratio of 3.58 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Dicerna Pharmaceuticals Receivables Over Time

Piotroski F Score   

Dicerna Pharmaceuticals Historical Liabilities

Total Debt

Did you try this?

Run Earnings Calls Now


Earnings Calls

Check upcoming earnings announcements updated hourly across public exchanges
All  Next Launch Module

Dicerna Pharmaceuticals Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Dicerna Pharmaceuticals and DelMar Pharmaceuticals. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Additionally see analysis of Dicerna Pharmaceuticals Fundamentals Over Time. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.
Search macroaxis.com